Insider Selling: Illumina (NASDAQ:ILMN) Insider Sells $123,000.00 in Stock

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 615 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total value of $123,000.00. Following the transaction, the insider directly owned 20,338 shares of the company’s stock, valued at $4,067,600. The trade was a 2.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Price Performance

Shares of ILMN stock opened at $199.87 on Thursday. The firm has a market cap of $30.18 billion, a P/E ratio of 37.29, a P/E/G ratio of 2.86 and a beta of 1.45. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $207.00. The business’s 50 day moving average price is $179.92 and its 200-day moving average price is $148.41. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current year.

Hedge Funds Weigh In On Illumina

Institutional investors and hedge funds have recently modified their holdings of the stock. Elyxium Wealth LLC bought a new position in Illumina in the 4th quarter worth about $25,000. Creative Capital Management Investments LLC raised its holdings in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after buying an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. bought a new position in shares of Illumina in the fourth quarter worth approximately $26,000. Laurel Wealth Advisors LLC bought a new position in shares of Illumina in the fourth quarter worth approximately $26,000. Finally, Elevation Wealth Partners LLC grew its holdings in shares of Illumina by 52.5% during the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after buying an additional 84 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ILMN has been the topic of several research analyst reports. Royal Bank Of Canada boosted their price target on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a report on Thursday, May 14th. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. JPMorgan Chase & Co. upped their target price on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Finally, Guggenheim increased their target price on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Illumina has an average rating of “Hold” and an average price target of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.